Exocarpium citri grandis fermented product for relieving respiratory tract inflammation induced by smoking as well as preparation method and application of exocarpium citri grandis fermented product

By using specific fermentation treatments to process Citrus reticulata powder, Citrus reticulata fermented products are prepared, which solves the problem of respiratory inflammation caused by smoking, significantly reduces inflammatory cell infiltration and inflammatory factor expression, and achieves stronger therapeutic effects and environmentally friendly and efficient industrial production.

CN118903282AActive Publication Date: 2024-11-08GUANGDONG XIAN LINGTONG BIOMEDICAL TECHNOLOGY CO LTD +1

Patent Information

Application Number
CN202411360092.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-27
Publication Date
2024-11-08
Estimated Expiration
2044-09-27

AI Technical Summary

Technical Problem

Existing technologies cannot effectively alleviate respiratory inflammation caused by smoking, and traditional methods such as e-cigarettes and cigarette filters cannot completely eliminate the effects of tobacco smoke on the respiratory system.

Method used

A specific fermentation method was used to process Citrus reticulata peel, including enzymatic hydrolysis and fermentation steps. Citrus reticulata peel powder was treated with compound enzymes and probiotics to prepare Citrus reticulata peel fermented products, which were used to reduce inflammatory cell infiltration in the respiratory tract and inhibit the expression of related inflammatory factors.

Benefits of technology

It significantly inhibited the infiltration of macrophages, neutrophils and lymphocytes, reduced the gene transcription levels of CCL2, CCL20, TNF-α, IL-1β and IL-6, provided a stronger therapeutic effect, and the preparation method is environmentally friendly and efficient, suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903282A_ABST
    Figure CN118903282A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines and health-care products, and discloses an exocarpium citri grandis fermented product for relieving respiratory tract inflammation induced by smoking, and a preparation method and application of the exocarpium citri grandis fermented product. The exocarpium citri grandis fermented product is a product obtained by fermenting exocarpium citri grandis by adding different compound enzymes and combined probiotics in multiple steps. The exocarpium citri grandis fermented product prepared by the invention can obviously improve the functional components of exocarpium citri grandis, enhance the anti-inflammatory effect on respiratory tract inflammation induced by tobacco smoke, and reduce the infiltration of respiratory tract inflammatory cells and the transcriptional level of inflammatory factors. The preparation method provided by the invention is high in operability, is easy to standardize and intelligentize, and can realize large-scale production in industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicines and health products, and particularly relates to a fermented tangerine peel product for relieving respiratory inflammation induced by smoking, a preparation method and an application thereof. Background Art

[0002] my country is the world's largest tobacco producer and consumer, with the largest tobacco production and consumption in the world. The "China Smoking Harm Health Report 2020" released by the National Health Commission pointed out that the number of smokers in my country exceeds 300 million. Although the smoking rate among the population is showing a downward trend, it is still at a high level. In particular, among people aged 15 and above, the smoking rate is 25.8%, among which the smoking rate among men is as high as 48.8%.

[0003] The tobacco industry has an important impact on my country's economy, but at the same time, smoking also brings serious health problems and social burdens. Tobacco smoke contains a large number of harmful substances, such as nicotine, carbon monoxide and various carcinogens, which pose a serious threat to the health of smokers. In addition, the problem of secondhand smoke is equally serious. In 2018, the secondhand smoke exposure rate of non-smokers in China was 68.1%. Long-term inhalation of smoke can lead to respiratory inflammation and various diseases, such as chronic obstructive pulmonary disease, asthma and lung cancer, which has brought a heavy burden to individual health and public health.

[0004] At present, although a variety of new tobacco preparations have been developed to reduce the harm of smoking, such as electronic cigarettes, cigarette filters and smokeless mouthpieces, these methods cannot completely eliminate the impact of tobacco smoke on the respiratory system. Therefore, it is necessary to develop drugs or health products that can effectively alleviate smoking-induced respiratory system inflammation to reduce the health risks of smokers and the people around them. Summary of the invention

[0005] In view of the above problems existing in the prior art, the present invention improves the effective ingredients of Citrus aurantium by a special fermentation method, and provides a Citrus aurantium fermentation product, a preparation method and an application thereof for alleviating respiratory inflammation induced by smoking.

[0006] The present invention adopts the following technical solution: In a first aspect of the present invention, there is provided a method for preparing a fermented product of Citrus aurantium wilfordii for relieving respiratory inflammation induced by smoking, comprising the following steps: S1: Disperse the tangerine peel powder evenly in a hydrochloric acid solution with a pH value of 5-6, add complex enzyme A, perform enzymolysis at 45-65°C for 1.5-3.5h, and collect the enzymolysis solution A after enzyme inactivation; S2: The pH value of the above enzymatic hydrolysate A is adjusted to 1.5-2, and the compound enzyme B is added, and the enzymatic hydrolysate is carried out at 37°C-39°C for 2-4 hours, and then the pH value is adjusted to 7.5-8.5, and the enzymatic hydrolysate B is collected after the enzyme is inactivated; S3: adding combined probiotics to the above enzymatic hydrolysate B for fermentation, collecting the fermentation liquid and freeze-drying it, and then sterilizing the microorganisms to obtain the fermented tangerine peel; In the step S1, the mass ratio of the tangerine peel powder and the hydrochloric acid solution is (1-2): (4-8); the complex enzyme A is a mixture of cellulase, glucosidase and amylase; In step S2, the compound enzyme B is a mixture of pepsin and trypsin; In step S3, the combination of probiotics is bifidobacterium, Lactobacillus rhamnosus and Lactobacillus reuteri.

[0007] Specifically, the added amount of the complex enzyme A accounts for 2-6 wt % of the amount of the tangerine peel powder; the mass ratio of cellulase, glucosidase and amylase in the complex enzyme A is (1-3): (2-4): (0.5-1).

[0008] Specifically, the added amount of the complex enzyme B accounts for 4-8 wt % of the amount of the tangerine peel powder; the mass ratio of pepsin to trypsin in the complex enzyme B is (0.5-2): (1-3).

[0009] Specifically, the added amount of the combined probiotics accounts for 1-5 wt% of the amount of the tangerine peel powder; the mass ratio of the bifidobacterium, Lactobacillus rhamnosus and Lactobacillus reuteri of the combined probiotics is (2-5): (4-7): (1-5).

[0010] Specifically, in step S3, the fermentation treatment is carried out at a temperature of 35° C. to 40° C. and for a time of 12 to 48 hours.

[0011] The second aspect of the present invention also provides a fermented product of Citrus aurantium wilfordii prepared by the method for relieving respiratory inflammation induced by smoking.

[0012] The third aspect of the present invention also provides the use of the prepared Citrus aurantium fermentation product in the preparation of medicines or health products for relieving respiratory inflammation induced by smoking.

[0013] Specifically, the medicine or health product for relieving smoking-induced respiratory inflammation is a medicine or health product that reduces the infiltration of macrophages, neutrophils and lymphocytes in the respiratory tract and inhibits the transcription levels of CCL2, CCL20, TNF-α, IL-1β and IL-6 genes.

[0014] Specifically, the fermented tangerine peel product can be made into medicines or health products such as tablets, granules, capsules or oral liquids.

[0015] Compared with the prior art, the present invention has the following beneficial effects: (1) The fermented product of the present invention is derived from the Chinese medicinal material Citrus aurantium, which is a natural plant ingredient. Compared with synthetic drugs or artificial chemicals, it is safer and non-toxic, has no side effects on human health, and meets the modern people's pursuit of health and nature.

[0016] (2) The present invention induces respiratory inflammation in mice by tobacco smoke, and treats the mice with the fermented product of Citrus aurantium, and finds that it can significantly inhibit the infiltration of macrophages, neutrophils and lymphocytes in the bronchoalveolar lavage fluid of mice, and significantly reduce the mRNA expression levels of CCL2, CCL20, TNF-α, IL-1β and IL-6. In addition, compared with unfermented Citrus aurantium, the fermented product of Citrus aurantium obtained by the present invention through a specific fermentation technology has a stronger therapeutic effect on tobacco smoke-induced respiratory inflammation, indicating that the preparation method used in the present invention is an innovative technical means and application method.

[0017] (3) The preparation method provided by the present invention is highly operable and easy to standardize and intelligentize. The fermentation process used is more environmentally friendly and efficient than the traditional extraction process, and can be mass-produced in industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The invention discloses the effect of the fermented product of Citrus aurantium on the transcription levels of CCL2, CCL20, TNF-α, IL-1β and IL-6 genes in the lung tissue of mice induced by tobacco smoke. DETAILED DESCRIPTION

[0019] The present invention is further described in detail below in conjunction with the embodiments. It should be noted that the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments, and the present application should not be construed as being limited to the specific embodiments described. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in the art without creative work are within the scope of protection of the present invention.

[0020] Example 1 This embodiment provides a method for preparing a fermented product of Citrus aurantium wilfordii for relieving respiratory inflammation induced by smoking, comprising the following steps: S1: 100 parts by weight of Citrus aurantium was powdered and evenly dispersed in 5 times the amount of hydrochloric acid solution with a pH value of 5.5, and 4 parts by weight of compound enzyme A was added, wherein the compound enzyme A was a mixture of cellulase, glucosidase and amylase, and the mass ratio of cellulase, glucosidase and amylase was 1:2.5:0.6, and enzymolysis was performed at 55°C for 2.5h, and the enzymolysis solution A was collected after enzyme inactivation treatment; S2: adjusting the pH value of the above enzymatic hydrolysate A to 1.6, adding 6 parts by weight of compound enzyme B, wherein the compound enzyme B is a mixture of pepsin and trypsin, and the mass ratio of pepsin to trypsin is 0.8:1.3, performing enzymolysis at 37.8°C for 2.5h, then adding NaOH to adjust the pH value to 8.2, and collecting the enzymatic hydrolysate B after enzyme inactivation treatment; S3: Add 3 parts by weight of combined probiotics to the above enzymatic hydrolysate B for fermentation, wherein the combined probiotics are bifidobacterium, Lactobacillus rhamnosus and Lactobacillus reuteri in a mass ratio of 3:5:2, and ferment at 37.5° C. for 24 hours. Collect the fermentation liquid and freeze-dry it, and then sterilize the microorganisms to obtain the finished product.

[0021] Example 2 This embodiment provides a method for preparing a fermented product of Citrus aurantium wilfordii for relieving respiratory inflammation induced by smoking, comprising the following steps: S1: 100 parts by weight of Citrus aurantium was powdered and evenly dispersed in 6 times the amount of hydrochloric acid solution with a pH value of 5.5, and 5 parts by weight of compound enzyme A was added, wherein the compound enzyme A was a mixture of cellulase, glucosidase and amylase, and the mass ratio of cellulase, glucosidase and amylase was 2:3:0.8, and enzymolysis was performed at 50°C for 3h, and the enzymolysis solution A was collected after enzyme inactivation treatment; S2: adjusting the pH value of the above enzymatic hydrolysate A to 1.6, adding 7 parts by weight of compound enzyme B, wherein the compound enzyme B is a mixture of pepsin and trypsin, and the mass ratio of pepsin to trypsin is 1:1.5, enzymolyzing at 37.8°C for 3h, then adding NaOH to adjust the pH value to 8.2, and collecting the enzymatic hydrolysate B after enzyme inactivation treatment; S3: Add 2 parts by weight of combined probiotics to the above enzymatic hydrolysate B for fermentation, wherein the combined probiotics are bifidobacterium, Lactobacillus rhamnosus and Lactobacillus reuteri in a mass ratio of 3:4:3, and ferment at 37.5°C for 18 hours. Collect the fermentation liquid and freeze-dry it, and then sterilize the microorganisms to obtain the finished product.

[0022] Example 3 This embodiment provides a method for preparing a fermented product of Citrus aurantium wilfordii for relieving respiratory inflammation induced by smoking, comprising the following steps: S1: 100 parts by weight of Citrus aurantium was powdered and evenly dispersed in 8 times the amount of hydrochloric acid solution with a pH value of 5.5, and 6 parts by weight of compound enzyme A was added, wherein the compound enzyme A was a mixture of cellulase, glucosidase and amylase, and the mass ratio of cellulase, glucosidase and amylase was 1:4:0.7, and enzymolysis was performed at 60°C for 2h, and the enzymolysis solution A was collected after enzyme inactivation treatment; S2: adjusting the pH value of the above enzymatic hydrolysate A to 1.6, adding 6.5 parts by weight of compound enzyme B, wherein the compound enzyme B is a mixture of pepsin and trypsin, and the mass ratio of pepsin to trypsin is 1:1.2, enzymolyzing at 37.8°C for 2.5h, then adding NaOH to adjust the pH value to 8.2, and collecting the enzymatic hydrolysate B after enzyme inactivation treatment; S3: Add 2.5 parts by weight of combined probiotics to the above enzymolysis solution B for fermentation, wherein the combined probiotics are bifidobacterium, Lactobacillus rhamnosus and Lactobacillus reuteri in a mass ratio of 2:3:3, and ferment at 37.5° C. for 30 hours. Collect the fermentation liquid and freeze-dry it, and then sterilize the microorganisms to obtain the finished product.

[0023] Comparative Example 1 The specific implementation is the same as Example 1, except that complex enzyme A is not added.

[0024] Comparative Example 2 The specific implementation is the same as in Example 1, except that complex enzyme B is not added.

[0025] Comparative Example 3 The specific implementation is the same as in Example 1, except that no combined probiotics are added.

[0026] Efficacy Test In order to verify that the fermented tangerine peel product of the present invention has the effect of alleviating smoking-induced respiratory inflammation, the following verification test was designed.

[0027] The animals used in this test were C57BL / 6 male mice, 8 weeks old, weighing 18-22g. All mice were adaptively fed for 7 days before the test. 64 mice were divided into 8 groups, namely, a blank control group, a model group, an embodiment 1-3 group, and a comparative example 1-3 group. Except for the blank control group, mice in other groups were all induced with tobacco smoke to induce respiratory inflammation models. The modeling method was as follows: 8 mice were placed in a smoke fumigation test box, and tobacco smoke was introduced, 4 times a day, 5 cigarettes each time, and the modeling period was 2 weeks. From the first day of modeling, the treatment group was gavaged with 50 mg / kg of the finished products prepared by embodiments 1-3 and comparative examples 1-3 every day for 2 weeks, and the blank control group and the model group were gavaged with an equal volume of normal saline.

[0028] (1) Respiratory inflammatory cell infiltration assay On the 15th day after modeling, mice were killed and endotracheal intubation was performed. 1 mL of HBSS buffer was infused through the endotracheal intubation for a total of 3 times. The 3 lavage solutions were combined and centrifuged, washed 2 times, and finally resuspended with 1 ml of HBSS buffer. Macrophages, neutrophils, and lymphocytes were counted using a cell automatic analyzer. The detailed results are shown in Table 1.

[0029] Table 1 Counts of macrophages, neutrophils and lymphocytes in bronchoalveolar lavage fluid of mice

[0030] As shown in Table 1, after tobacco smoke induction, the number of macrophages, neutrophils and lymphocytes in the bronchoalveolar lavage fluid of mice increased significantly. After the finished product treatment in Examples 1 to 3 and Reference Examples 1 to 3, the number of macrophages, neutrophils and lymphocytes in the bronchoalveolar lavage fluid of mice decreased to varying degrees. Among them, the effect of Example 1 to 3 groups was significantly better than that of Reference Example 1 to 3 groups. And in combination with the comparative example, it can be seen that after the embodiment of the present invention adopts the composite enzyme A and B and the probiotics composite treatment, the effect of the obtained tangerine peel fermentation product is significantly higher than the fermentation obtained by a single composite enzyme or probiotics, which illustrates that there is a synergistic effect between the composite enzymes of the present invention and the probiotics, which can cooperate with each other, support each other, and have a better effect.

[0031] (2) Determination of mRNA expression levels of inflammatory factors The therapeutic effects of the finished products in Examples 1 to 3 and Comparative Examples 1 to 3 on tobacco smoke-induced respiratory inflammation were further evaluated by detecting the mRNA expression levels of inflammatory factors in lung tissue. Figure 1 As shown, the finished products in Examples 1 to 3 and Control Examples 1 to 3 reduced the mRNA expression levels of tobacco smoke-induced inflammatory factors, including CCL2, CCL20, TNF-α, IL-1β and IL-6, to varying degrees. Similarly, the effects of Examples 1 to 3 were significantly better than those of Control Examples 1 to 3.

[0032] Based on the above test results, the fermented tangerine peel provided by the present invention can significantly improve the therapeutic effect on tobacco smoke-induced respiratory inflammation, thereby achieving the effect of inhibiting the infiltration of inflammatory cells and reducing the transcription level of inflammatory factors.

[0033] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for preparing a fermented product of Citrus aurantium wilfordii for relieving respiratory inflammation induced by smoking, characterized in that: The following steps are involved: S1: Disperse the tangerine peel powder evenly in a hydrochloric acid solution with a pH value of 5-6, add complex enzyme A, perform enzymolysis at 45-65°C for 1.5-3.5h, and collect the enzymolysis solution A after enzyme inactivation; S2: The pH value of the above enzymatic hydrolysate A is adjusted to 1.5-2, and the compound enzyme B is added, and the enzymatic hydrolysis is carried out at 37°C-39°C for 2-4 hours, and then the pH value is adjusted to 7.5-8.5, and the enzymatic hydrolysate B is collected after the enzyme is inactivated; S3: adding combined probiotics to the above enzymatic hydrolysate B for fermentation, collecting the fermentation liquid and freeze-drying it, and then sterilizing the microorganisms to obtain the fermented tangerine peel; In the step S1, the mass ratio of the tangerine peel powder to the hydrochloric acid solution is (1-2): (4-8); the complex enzyme A is a mixture of cellulase, glucosidase and amylase; In step S2, the compound enzyme B is a mixture of pepsin and trypsin; In step S3, the combination of probiotics is bifidobacterium, Lactobacillus rhamnosus and Lactobacillus reuteri.

2. The method for preparing the fermented product of Citrus aurantium according to claim 1, characterized in that: The added amount of the complex enzyme A accounts for 2-6 wt % of the amount of the tangerine peel powder; the mass ratio of cellulase, glucosidase and amylase in the complex enzyme A is (1-3): (2-4): (0.5-1).

3. The method for preparing the fermented product of Citrus aurantium according to claim 1, characterized in that: The added amount of the complex enzyme B accounts for 4-8 wt % of the amount of the tangerine peel powder; the mass ratio of pepsin to trypsin in the complex enzyme B is (0.5-2): (1-3).

4. The method for preparing the fermented product of Citrus aurantium according to claim 1, characterized in that: The added amount of the combined probiotics accounts for 1-5 wt% of the amount of the tangerine peel powder; the mass ratio of the bifidobacterium, Lactobacillus rhamnosus and Lactobacillus reuteri of the combined probiotics is (2-5): (4-7): (1-5).

5. The method for preparing the fermented product of Citrus aurantium according to claim 1, characterized in that: In step S3, the fermentation treatment is carried out at a temperature of 35° C. to 40° C. and for a time of 12 to 48 hours.

6. A fermented product of Citrus aurantium wilfordii for relieving smoking-induced respiratory inflammation prepared by the method according to any one of claims 1 to 5.

7. Use of the fermented product of Citrus aurantium according to claim 6 in the preparation of medicines or health products for relieving respiratory inflammation induced by smoking.

8. The use according to claim 7, characterized in that: The medicine or health product for relieving respiratory inflammation induced by smoking is a medicine or health product that reduces the infiltration of macrophages, neutrophils and lymphocytes in the respiratory tract and inhibits the transcription levels of CCL2, CCL20, TNF-α, IL-1β and IL-6 genes.

9. The use according to claim 7, characterized in that: The medicine or health product is in the form of tablets, granules, capsules or oral liquids.

Citation Information

Patent Citations

  • Probiotics fermented Chinese herbal composition capable of dispelling effect of alcohol and protecting liver and preparing method and application thereof

    CN106266105A

  • Probiotic composition for enhancing lung function as well as preparation and application thereof

    CN114164141A

  • Composition of prebiotics and probiotic compound and application thereof

    WO2023070513A1

  • Use of exocarpium citri grandis productive cough extract in preparation of drug for inhibiting human coronavirus infection

    WO2023273558A1

Cited By

  • Exocarpium powder for respiratory tract health as well as preparation method and application of exocarpium powder

    CN119925481A